• Single Use In Biopharma: Beyond Savings & Sustainability

    SUT continues to trend in biopharmaceutical applications, driven largely by environmental and economic considerations. But there’s a lot more to the SUT story, including supply chain and standardization advantages. On April 24 at 11 AM ET, we’re diving into it live with independent SUT expert Paul Priebe and Krystal Biotech VP of Technical Operations Mark Petrich.

  • Eying Up The Era Of Topical Biologics

    Claris Bio’s phase 1/2 clinical trial in patients with Stage 2 or 3 Neurotrophic Keratitis (NK) is breaking new ground in the development of topically administered biologic therapies. 

  • Doubling Down On Biopharma’s Growing Skills Drought

    The biopharmaceutical industry is building manufacturing capacity at breakneck speed. According to PhRMA, there are 1,580-and-counting biopharma manufacturing facilities in the U.S. alone. Problem is, we're way short on filling those facilities with skilled labor. NIIMBL wants to change that. Here's how, and a great opportunity for big pharma, biotech sponsors, CDMOs, academics, and more to help.

  • Debra Weiss, RN: Big Impact In Small, Non-Profit Bio

    The career of Debra Weiss, RN, MSN, and COO at the biopharma Gates Medical Research Institute (Gates MRI), offers a case study in creating success through service-oriented leadership.

  • U.S. Biotech Is In For A Protracted Divorce From China

    The U.S. imported $6.95 billion worth of pharmaceuticals from China in 2022. That was 8x the amount we imported in 2021. A proposed Act of Congress puts that supply, and U.S. biotech itself, in serious peril.

  • 1 In 300 People In The U.S. Is Living With HIV. That’s Not Okay With Jeff Galvin.

    By modifying CD4 T cells using miRNA, Jeff Galvin’s company thinks it can deliver a functional cure for HIV. Here’s the ongoing story of Addimmune and its unique clinical strategy.

  • 3 Things You Didn’t Hear Coming Out Of JPM

    You’ve heard San Francisco was buzzing with cautious optimism last month. You’ve seen the M&A activity that’s buoying spirits and you know inflation and interest rates are stabilizing, if not improving. You may not have considered these three trendlines, offered by a guy who spent his time at JPM doing more listening than anything. 

  • Legal And IP Protection For New Biotechs

    Want to ensure you've got your biotech legal, IP, and patent bases covered? Join Business of Biotech host Matt Pillar and BlueSphere Bio CEO and biotech legal expert Keir LoIacono on 11/13 for the live, interactive, and FREE digital event Legal And IP Protection For New Biotechs. 

  • Tech-Heavy Drug Discovery Yields Deep Pipeline

    Recursion Cofounder and CEO, Chris Gibson, Ph.D. is creating a map of human biology comparable to Google’s ongoing effort to map every street on the planet. He shared why that's so important, and how it's informing Recursion's rapid drug discovery efforts.

  • Engineering Antibodies In A Box?

    Machines aren’t smart enough to engineer optimal, disease-specific antibodies without data that’s properly generated, captured, and structured. That’s why LabGenius Founder Dr. James Field says the key to success is neither human-derived data, nor machine-enabled design. It’s the organizational engineering feat of bringing the two together.

  • Why RNA Is Good For Business

    Early last year, Nutcracker Therapeutics landed a $170 million Series C to further its work developing an RNA drug development platform. Learn how scientist-turned Chief Business Officer Geoff Nosrati is lifting the company above the cacophony of companies rallying around the therapeutic potential of RNA.

  • Key Biomanufacturing Ingredient In Short Supply

    Biopharma supply chains and manufacturing capacity are on the comeback trail, but one of the key requirements for sustainable development and manufacturing success remains elusive. NIIMBL Workforce Director John Balchunas shares perspective from a unique vantage point.

  • Where Oncology Drug Discovery Goes Next

    AbbVie Bay Area Site Head and VP of Oncology Discovery Research Steve Davidsen, Ph.D. lays out the primary challenges to pushing forward in areas of high, unmet oncological need: accelerating discovery to shorten the time to patient impact and identifying optimal patients for a given mechanism of action or molecule.

  • Immunome’s Platform Partnership Potential

    Immunome’s discovery engine caught AbbVie’s eye, nabbing the biotech a transformative deal. CEO Purnanand Sarma, Ph.D. and CFO Corleen Roche take us behind the scenes.

  • Active ADC Space Challenges Development Strategies

    Payload and linker technology advances have contributed to an explosion in antibody-drug conjugate development in recent years, amd the funding has followed. But, while the face value of ADC activity represents a bright spot in an otherwise sluggish biotech investment environment, the challenges of doing business in a hotly competitive market are playing out.

  • Anatomy Of A Biopharma VC Deal

    Why does a venture capitalist choose to fund a biopharma company? What prompts them to choose not to? And why should (or shouldn't) a biopharma company take a VC's money?

  • Topical Biologics In Ophthalmology?

    A recent clinical study of an eyedrop formulated with Grifols’ Immunoglobulin-based Flebogamma DIF offers cause for optimism among multiple stakeholders. It could become the first-approved topically administered biologic therapy for dry eye disease. 

  • AAV Manufacturing Field: An Interactive Look

    Mapping the adeno-associated virus (AAV) therapeutic space gives us a glimpse into indication priorities for gene therapy, and a look at whose got their fingers in which partners’ pots. Check out this interactive graphic from DeciBio Principal Carl Schoellhammer, Ph.D. It's not only instructive, its kind of therapeutic to play with. 

  • Cashing In On Biopharma Collaboration

    How does a biopharma business that’s potentially years away from its first shot at therapeutic sales revenue thrive in a high-inflation, high-interest, supply-constrained business environment?

  • What’s In A “Biopharma” Name?

    As exciting new modalities, hybrids, and conjugates blur therapeutic lines, let’s not forget what “bio” means, how biologic therapeutics are distinguished, and why they were delineated as such in the first place. Make sure you're not a BINO (Bio In Name Only) when you’re naming your “biotech.”

  • FDA Submission Automation: Coming To A Cloud Near You

    The FDA is laying the groundwork for standardized, cloud-based electronic submission standards via an initiative that leverages data automation and artificial intelligence. What will it mean to biopharma filers?

  • Bench To Boardroom: A Scientist-Turned-CEO’s Journey

    Novadip Biosciences CEO Denis Dufrane, M.D., Ph.D. got a crash course in biopharma leadership, but not before he left cell therapy research on his own timeframe. He sat down with Bioprocess Online to tell us what he learned.

  • Antibody-Drug Conjugates: Increasing Investment In R&D And Partnerhip

    DeciBio’s Antibody-Drug Conjugates 2023 Industry Survey points to progress in ADC development. Respondents anticipate lower regulatory, financial, and R&D barriers as the technology matures. Senior Life Science Expert Joe Daccache, Ph.D. gave us an insider's look at the numbers.

  • What's True Of Mice ≠ What's True Of Men

    After losing his mother to pancreatic cancer, entrepreneur Alex Blyth launched an immuno-oncology company that’s developing a novel allogeneic cell therapy. The company, LIfT BioSciences, recently received a shot in the arm when it was accepted into Johnson & Johnson Innovation’s JLABS network.

  • Can JP Morgan Help San Francisco?

    My first in-person JP Morgan Healthcare Conference was great for business. It also left me wondering what the world's toniest healthcare conference is doing for the health of its ailing host city.


Matthew Pillar

Matthew Pillar is chief editor at Bioprocess Online. He's spent the past 20 years covering tech-centric industries as they’ve navigated AI, machine learning, IoT, and other emerging technologies. His chief and executive editorial experience includes tenures with Software Executive, Channel Executive, Business Solutions and ISR magazines, where he routinely interviewed international technology builders and influencers. Pillar has spoken on emerging technologies and their implications at major events for leading tech vendors including NetSuite, Oracle, SAP, and others.

Connect with Pillar on LinkedIn at